Healthcare Global Enterprises Ltd. · NSE:HCG
Healthcare Global Enterprises — J.P. Morgan Healthcare Conference 2020
22 slides from Healthcare Global Enterprises's conference presentation, Jan 17, 2020
Slide 1: Exchange filing cover letter: Investor Presentation
January 17, 2020 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai – 400 051, Dalal Street, Mumbai – 400 001, Maharashtra, India Maharashtra, India Dear Sirs, Sub
Slide 2: HealthCare Global Enterprises Ltd.
HealthCare Global Enterprises Ltd.
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. This pr
Slide 4: Overview
Overview Snapshot of the Business Specialty healthcare provider with a Comprehensive cancer diagnosis focus on cancer and fertility and treatment services Largest1 provider of cancer care in Cancer 226 comprehensive cancer centers, Care India under the HCG brand Leading provider of fertili
Slide 5: India's Leading Provider of Cancer Care
India’s Leading Provider of Cancer Care Center of Excellence (1)1 Comprehensive Cancer Center (21)2 Cancer Centers Under Development (2) Delhi/NCR Jaipur 1,654 O P E R A T I O NA L BEDS Ahmedabad Ranchi Kolkata Bhavnagar Nagpur Baroda Cuttack Nashik Mumbai Vishakhapatanam 28 16 Gulbarga LINEAR PET-C
Slide 6: Comparable outcomes at a fraction of the cost
Comparable outcomes at a fraction of the cost 5
Slide 7: Scale of the Oncology Business 2016-19
Scale of the Oncology Business 2016-19 No. of Centres Beds New Patients Gujarat FY19 FY19: 31% FY19 Karnataka (25%) 1 21 1,524 72,110 36% (49%)1 FY16: FY16: FY16: 15 1,028 43,714 65% Maharashtra North India 13% Average Occupancy ALOS (Days) ARPOB ($/ Day) 2% (5%) 1 FY190 FY19: FY19 Tamil Nadu East I
Slide 8: Growth supported by profitability of centres
Growth supported by profitability of centres Revenue (INR Mn) Fiscal Year ended March 31 As on 30th Sept’ 2019 ~ 9,787 8,307 7,001 Existing Existing Center(1) Center(1) 5,842 EBITDA ROCE 5,194 Margin 18.4% 4,513 21.5% 3,383 2,666 2,148 (1) Excludes new centres that started 1,600 operation since Apri
Slide 9: Strategies
Strategies Singular organization focus/alignment on growth at Existing Centres Capacity / cost optimization measures Existing Centres Cohesive engagement among clinical, sales and admin/operations Stabilize operations; drive towards break-even at Borivali, S Mumbai, Kolkata Centres New Cente
Slide 10: Strand Lifesciences Pvt. Ltd. - November 2019
Strand Lifesciences Pvt. Ltd. - CONFIDENTIAL November 2019
Slide 11: A unique global precision medicine solutions provider
A unique global precision medicine solutions provider offering informatics, software, assay design & validation, and clinical research solutions Assay Informatics Clinical Design & & Software Research Validation 10
Slide 12: Over 25,000 peer reviewed citations for informatics tools we have helped build
Over 25,000 peer reviewed citations for informatics tools we have helped build Mass Integrated Sequencing Microarrays Spectrometry Omics 11
Slide 13: Long-term relationships with major instrument and diagnostics companies
Long-term relationships with several major instrument and diagnostics companies, including for regulatory submissions Natural User Visualizations Algorithms Language Interfaces Processing 12
Slide 14: Variant databases with therapeutic implications for clinical reporting
Variant databases with therapeutic implications for clinical reporting, used to drive >10,000 CAP/CLIA somatic profiling reports >15,000 >800 >50000 >500 Clinical Variants Drugs Genes Trials 13
Slide 15: Complex genomic assay design, CAP/CLIA validation, and Companion Dx partnerships
Complex genomic assay design, CAP/CLIA validation, IUO design & validation, Single site PMAs, & partnerships for Companion Dx global roll-out Luminex, ~10-5000 qPCR, ~0.1% ELISA, genes MLPA etc LLoD Nanostring Medium & Targeted Solid and Large Gene Gene Liquid RNA/Protein Panels Assays Biopsies 14
Slide 16: Strand is a key member of the Global Diagnostics Network anchored by Quest Diagnostics
Strand is a key member of the Global Diagnostics Network anchored by Quest Diagnostics, with partners in all key geographies, including the US, Europe and China, enabling single-window roll-out of Companion Diagnostics 15
Slide 17: Strand lab network across India and Quest Dx India acquisition
Strand operates a network of 19 labs across India (3 of which are CAP-accredited) performing 1.5m tests annually across histopathology, flow cytometry, biochemistry, molecular Dx, and NGS. Strand recently acquired Quest Dx’s India business. 16
Slide 18: Strand is a pioneer of genomic testing in India
Strand is a pioneer of genomic testing in India, with experience in running ~15,000 genomic tests spanning rare diseases, inherited cancer risk, somatic profiling, and liquid biopsy profiling 17
Slide 19: Exclusive strategic relationship with HCG
Strand, through its exclusive strategic relationship with HCG, India’s largest specialist oncology hospital chain, has access to ~30,000 cancer patients and over ~100,000 biorepository tumor blocks and associated medical data for translational research and clinical trials 18
Slide 20: Testimonials
Testimonials It is tough to beat Strand NGS Strand NGS can handle 1000s of RNAseq for painless data exploration, samples. I like this product. So, please well thought out GUI and concise but keep improving or adding features for highly functional toolset and statistics, customers. Roy Williams, Aspe
Slide 21: Strand's ~200 strong team
Strand’s ~200 strong team comprises computer scientists, bioinformaticians, geneticists, molecular bench biologists, pathologists and clinical research personnel, all under one roof, with very strong R&D capabilities >40 >40 >50 >25 Informaticians & Molecular & Geneticists & M.D. Software Bench Mol.
Slide 22: Thank You
Thank You gganapati@hcgel.com ramesh@strandls.com
HealthCare Global Enterprises — J.P. Morgan Healthcare Conference 2020 on 6ix